Heron Therapeutics (HRTX) Stock Forecast & Price Target

Heron Therapeutics is supported by a commercial portfolio that still generates meaningful cash flow, especially from CINVANTI, which is forecast to contribute $97.3M of 2026 revenue and help fund investment in ZYNRELEF. Its positive case centers on ZYNRELEF’s ability to scale from $10.2M in 1Q26 to $56.0M for full-year 2026, an execution test that could offset patent-related pressure on the cash runway if CINVANTI exclusivity is lost. Confidence is further reinforced by strong clinical results from Exparel, which appear to strengthen the broader post-operative pain market and validate demand for hospital and outpatient therapies.

Heron Therapeutics is facing a deteriorating fundamental profile because the adverse CINVANTI patent ruling removed the company’s main revenue and cash-flow anchor, creating uncertainty around a generic launch and forcing withdrawal of 2026 revenue and Adjusted EBITDA guidance. With CINVANTI contributing about 60% of topline and $42.3M of the $72.4M generated in 1H26, the remaining businesses are not yet large enough to offset a potential sales decline, especially as ZYNRELEF’s $11.1M quarterly revenue and slower-than-needed ramp have not matched prior expectations. The balance sheet compounds the risk, as 2Q26 ended with $42.7M of cash against about $142.7M of debt, while covenant amendments, required principal paydowns, paused sales-force expansion, and a strategic-alternatives process all point to constrained financial flexibility.